| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2864868 | The American Journal of the Medical Sciences | 2009 | 8 Pages |
Abstract
Despite significant improvement in HOMA-β index and PI/IR from placebo, there does not seem to be a benefit of dipeptidyl peptidase-IV inhibitors over other agents with respect to β-cell function/activity. Long-term prevention of β-cell dysfunction cannot be ruled out.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Daniel M. PharmD, BCPS, Honey E. MD, Krista D. PharmD, BCPS,